Wanbury Ltd

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 3 August 2026. This adjustment reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals. Despite strong long-term growth and robust profitability metrics, concerns over elevated debt levels and a shift in technical indicators have tempered investor enthusiasm.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a nuanced market sentiment. Despite a recent downgrade from a Buy to a Hold rating by MarketsMOJO on 3 August 2026, the stock’s price action and technical indicators reveal a complex interplay of bullish and bearish signals that investors should carefully analyse.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy as of 27 July 2026. This upgrade reflects a comprehensive reassessment of the company’s valuation, financial trends, quality metrics, and technical indicators, signalling renewed investor confidence amid robust operational performance and attractive market positioning.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 21 July 2026. This revision reflects a shift in valuation metrics alongside a nuanced assessment of the company’s financial trends, quality parameters, and technical outlook. Despite robust operational performance and impressive long-term returns, concerns over valuation and debt levels have tempered enthusiasm among investors.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid strong operational metrics and a competitive peer landscape, prompting investors to reassess the stock’s price attractiveness relative to historical and sector benchmarks.

Wanbury Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone on 15 Jul 2026 by touching a new 52-week and all-time high of Rs.360. This achievement marks a continuation of the stock’s strong upward momentum, reflecting robust performance metrics and positive market dynamics.

Extending a remarkable five-day winning streak, Wanbury Ltd surged to a fresh all-time high of Rs 352.95 on 15 Jul 2026, outperforming its sector and the broader market with a 5.19% gain on the day.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy, reflecting significant improvements across technical indicators, valuation metrics, financial trends, and overall quality. This upgrade, effective from 14 July 2026, comes amid a strong rally in the stock price and encouraging quarterly results, signalling renewed investor confidence in the company’s prospects.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant price momentum shift, reflected in a robust 11.75% gain on 15 Jul 2026. This surge accompanies an upgrade in its MarketsMOJO Mojo Grade from Hold to Buy, signalling renewed investor confidence bolstered by a confluence of bullish technical indicators across multiple timeframes.

Wanbury Ltd, a key player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high price of Rs.347.1 on 14 July 2026, marking a significant milestone in its market journey. This achievement reflects the company’s robust performance and sustained upward momentum over recent months.

With a decisive surge to Rs 347.1 on 14 Jul 2026, Wanbury Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This rally is underscored by a strong alignment of technical indicators and sustained gains over the past four sessions, reflecting robust upward momentum despite a broadly subdued market backdrop.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 13 July 2026. This adjustment reflects a nuanced shift across key evaluation parameters including quality, valuation, financial trends, and technical indicators, signalling a more cautious stance despite the company’s robust long-term performance.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a transition from a bullish to a mildly bullish trend. Recent price movements and technical indicators such as MACD, RSI, Bollinger Bands, and moving averages reveal a complex picture that investors should carefully analyse amid the stock’s strong relative performance against the Sensex.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy as of 9 July 2026. This upgrade reflects a marked improvement across key parameters including technical indicators, valuation metrics, financial trends, and overall quality scores, signalling renewed investor confidence in the stock’s growth prospects.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in technical momentum, upgrading its outlook from mildly bullish to bullish. This change accompanies a robust price performance, with the stock surging 5.9% in a single day and delivering impressive returns well above the Sensex over multiple timeframes.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 1 July 2026. This adjustment reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals. Despite robust long-term growth and strong quarterly financials, concerns around technical indicators and elevated debt levels have tempered enthusiasm among analysts.